Stay up to date with our latest research
and corporate developments

The anti-cancer drug, CVM-1118, has received approval from China’s National Medical Products Adminis…

[Read More]

TaiRx’s orally administered anticancer drug, CVM-1118 (Foslinanib), was officially granted Orphan Dr…

[Read More]

TaiRx, Inc. hereby declares that Zelnite® is the only selenium injection product with a drug license

[Read More]

In 2018, TaiRx received approval from the Food and Drug Administration (TFDA) of the Ministry of Hea…

[Read More]